Romosozumab for the treatment of osteoporosis

Bandeira, L; Lewiecki, EM; Bilezikian, JP

Lewiecki, EM (reprint author), New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.

EXPERT OPINION ON BIOLOGICAL THERAPY, 2017; 17 (2): 255

Abstract

Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a......

Full Text Link